-
1
-
-
59149085501
-
The global burden of hepatitis C
-
Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
-
(2009)
Liver Int.
, vol.29
, Issue.SUPPL. 1
, pp. 74-81
-
-
Lavanchy, D.1
-
2
-
-
79958748633
-
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
-
Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30-60.
-
(2011)
Liver Int.
, vol.31
, Issue.SUPPL. 2
, pp. 30-60
-
-
Cornberg, M.1
Razavi, H.A.2
Alberti, A.3
Bernasconi, E.4
Buti, M.5
Cooper, C.6
-
3
-
-
80955167606
-
Prevalence and risk factors of HCV infection in Poland
-
Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011;23(12):1213-7.
-
(2011)
Eur J Gastroenterol Hepatol.
, vol.23
, Issue.12
, pp. 1213-1217
-
-
Flisiak, R.1
Halota, W.2
Horban, A.3
Juszczyk, J.4
Pawlowska, M.5
Simon, K.6
-
4
-
-
78650766355
-
Hepatitis C virus: How genetic variability affects pathobiology of disease
-
Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26 Suppl 1:83-95.
-
(2011)
J Gastroenterol Hepatol.
, vol.26
, Issue.SUPPL. 1
, pp. 83-95
-
-
Chayama, K.1
Hayes, C.N.2
-
5
-
-
33747797031
-
Treating viral hepatitis C: Efficacy, side effects, and complications
-
Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-9.
-
(2006)
Gut.
, vol.55
, Issue.9
, pp. 1350-1359
-
-
Manns, M.P.1
Wedemeyer, H.2
Cornberg, M.3
-
6
-
-
78349285127
-
Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin
-
Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30(9):1259-69.
-
(2010)
Liver Int.
, vol.30
, Issue.9
, pp. 1259-1269
-
-
Asselah, T.1
Estrabaud, E.2
Bieche, I.3
Lapalus, M.4
De Muynck, S.5
Vidaud, M.6
-
7
-
-
58149380829
-
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors
-
Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008;48(6):1753-60.
-
(2008)
Hepatology.
, vol.48
, Issue.6
, pp. 1753-1760
-
-
Shirakawa, H.1
Matsumoto, A.2
Joshita, S.3
Komatsu, M.4
Tanaka, N.5
Umemura, T.6
-
8
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-9.
-
(2009)
Nat Genet.
, vol.41
, Issue.10
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
Kurosaki, M.4
Matsuura, K.5
Sakamoto, N.6
-
9
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-4.
-
(2009)
Nat Genet.
, vol.41
, Issue.10
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
Berg, T.4
Weltman, M.5
Abate, M.L.6
-
10
-
-
77949831342
-
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study
-
1338-45-45+e1-e7
-
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-45-45 e1-7.
-
(2010)
Gastroenterology.
, vol.138
, Issue.4
-
-
Rauch, A.1
Kutalik, Z.2
Descombes, P.3
Cai, T.4
Di Iulio, J.5
Mueller, T.6
-
11
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
-
(2009)
Nature.
, vol.461
, Issue.7262
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
-
12
-
-
70349966196
-
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
-
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
-
(2009)
Nature.
, vol.461
, Issue.7265
, pp. 798-801
-
-
Thomas, D.L.1
Thio, C.L.2
Martin, M.P.3
Qi, Y.4
Ge, D.5
O'Huigin, C.6
-
13
-
-
0026458517
-
A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested
-
Lahiri DK, Bye S, Nurnberger JI, Jr, Hodes ME, Crisp M. A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested. J Biochem Biophys Methods. 1992;25(4):193-205.
-
(1992)
J Biochem Biophys Methods.
, vol.25
, Issue.4
, pp. 193-205
-
-
Lahiri, D.K.1
Bye, S.2
Nurnberger Jr., J.I.3
Hodes, M.E.4
Crisp, M.5
-
14
-
-
84878239932
-
Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
-
Domagalski K, Pawlowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, et al. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis. 2013;32(6):745-54.
-
(2013)
Eur J Clin Microbiol Infect Dis.
, vol.32
, Issue.6
, pp. 745-754
-
-
Domagalski, K.1
Pawlowska, M.2
Tretyn, A.3
Halota, W.4
Pilarczyk, M.5
Smukalska, E.6
-
15
-
-
77954225315
-
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes
-
Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52(1):33-7.
-
(2010)
Hepatology.
, vol.52
, Issue.1
, pp. 33-37
-
-
Montes-Cano, M.A.1
Garcia-Lozano, J.R.2
Abad-Molina, C.3
Romero-Gomez, M.4
Barroso, N.5
Aguilar-Reina, J.6
-
16
-
-
77952693487
-
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
-
McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138(7):2307-14.
-
(2010)
Gastroenterology.
, vol.138
, Issue.7
, pp. 2307-2314
-
-
McCarthy, J.J.1
Li, J.H.2
Thompson, A.3
Suchindran, S.4
Lao, X.Q.5
Patel, K.6
-
17
-
-
79952899824
-
Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C
-
344-50e2
-
Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(4):344-50 e2.
-
(2011)
Clin Gastroenterol Hepatol.
, vol.9
, Issue.4
-
-
Stattermayer, A.F.1
Stauber, R.2
Hofer, H.3
Rutter, K.4
Beinhardt, S.5
Scherzer, T.M.6
-
18
-
-
84858134441
-
The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b
-
Mach T, Ciesla A, Sanak M, Glowacki MK, Warunek W, Owczarek D. The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b. Prz Gastroenterol. 2012;7(1):38-42.
-
(2012)
Prz Gastroenterol.
, vol.7
, Issue.1
, pp. 38-42
-
-
Mach, T.1
Ciesla, A.2
Sanak, M.3
Glowacki, M.K.4
Warunek, W.5
Owczarek, D.6
-
19
-
-
84871855792
-
The occurrence of HCV genotypes and single polynucleotide polymorphisms of rs12979860 among HCV infected patients in northeastern Poland
-
Kozlowski P, Pogorzelska J, Lapinski TW, Kowalczuk O, Niklinski J, Flisiak R. [The occurrence of HCV genotypes and single polynucleotide polymorphisms of rs12979860 among HCV infected patients in northeastern Poland]. Przegl Epidemiol. 2012;66(2):335-9.
-
(2012)
Przegl Epidemiol.
, vol.66
, Issue.2
, pp. 335-339
-
-
Kozlowski, P.1
Pogorzelska, J.2
Lapinski, T.W.3
Kowalczuk, O.4
Niklinski, J.5
Flisiak, R.6
-
20
-
-
80052660473
-
A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus
-
Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, et al. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol. 2011;23(10):931-5.
-
(2011)
Eur J Gastroenterol Hepatol.
, vol.23
, Issue.10
, pp. 931-935
-
-
Halfon, P.1
Bourliere, M.2
Ouzan, D.3
Maor, Y.4
Renou, C.5
Wartelle, C.6
-
21
-
-
84871976557
-
Meta-analysis: Implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
-
Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6.
-
(2013)
BMC Med.
, vol.11
, pp. 6
-
-
Jimenez-Sousa, M.A.1
Fernandez-Rodriguez, A.2
Guzman-Fulgencio, M.3
Garcia-Alvarez, M.4
Resino, S.5
-
22
-
-
84856189254
-
Host genomics and HCV treatment response
-
Clark PJ, Thompson AJ. Host genomics and HCV treatment response. J Gastroenterol Hepatol. 2012;27(2):212-22.
-
(2012)
J Gastroenterol Hepatol.
, vol.27
, Issue.2
, pp. 212-222
-
-
Clark, P.J.1
Thompson, A.J.2
-
23
-
-
80055047790
-
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin
-
Scherzer TM, Stattermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology. 2011;54(5):1518-26.
-
(2011)
Hepatology.
, vol.54
, Issue.5
, pp. 1518-1526
-
-
Scherzer, T.M.1
Stattermayer, A.F.2
Strasser, M.3
Laferl, H.4
Maieron, A.5
Stauber, R.6
-
24
-
-
84984584308
-
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
-
Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, et al. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Antivir Ther. 2012;17(6):1059-67.
-
(2012)
Antivir Ther.
, vol.17
, Issue.6
, pp. 1059-1067
-
-
Liu, C.H.1
Liang, C.C.2
Liu, C.J.3
Tseng, T.C.4
Lin, C.L.5
Yang, S.S.6
-
25
-
-
79960382329
-
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
-
Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol. 2011;55(5):980-8.
-
(2011)
J Hepatol.
, vol.55
, Issue.5
, pp. 980-988
-
-
Bochud, P.Y.1
Bibert, S.2
Negro, F.3
Haagmans, B.4
Soulier, A.5
Ferrari, C.6
-
26
-
-
77953881002
-
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
-
120-9e18
-
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-9 e18.
-
(2010)
Gastroenterology.
, vol.139
, Issue.1
-
-
Thompson, A.J.1
Muir, A.J.2
Sulkowski, M.S.3
Ge, D.4
Fellay, J.5
Shianna, K.V.6
-
27
-
-
84873707575
-
Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin
-
Jablonowska E, Piekarska A, Koslinska-Berkan E, Omulecka A, Szymanska B, Wojcik K. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Acta Biochim Pol. 2012;59(3):333-7.
-
(2012)
Acta Biochim Pol.
, vol.59
, Issue.3
, pp. 333-337
-
-
Jablonowska, E.1
Piekarska, A.2
Koslinska-Berkan, E.3
Omulecka, A.4
Szymanska, B.5
Wojcik, K.6
-
28
-
-
78049465963
-
A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels
-
Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology. 2010;139(5):1794-6.
-
(2010)
Gastroenterology.
, vol.139
, Issue.5
, pp. 1794-1796
-
-
Lindh, M.1
Lagging, M.2
Norkrans, G.3
Hellstrand, K.4
|